CN102525889A - Ornidazole ophthalmic gel and preparation method and application thereof - Google Patents
Ornidazole ophthalmic gel and preparation method and application thereof Download PDFInfo
- Publication number
- CN102525889A CN102525889A CN2012100711413A CN201210071141A CN102525889A CN 102525889 A CN102525889 A CN 102525889A CN 2012100711413 A CN2012100711413 A CN 2012100711413A CN 201210071141 A CN201210071141 A CN 201210071141A CN 102525889 A CN102525889 A CN 102525889A
- Authority
- CN
- China
- Prior art keywords
- ornidazole
- gel
- eye use
- eye
- consumption
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses ornidazole ophthalmic gel and a preparation method and application thereof, belongs to the technical field of medicine, and relates to ornidazole serving as an active medicament ingredient. The ornidazole is prepared into the ophthalmic gel for the first time, and the gel is used for preventing and treating blepharitis, hordeolum and conjunctivitis caused by infection of demodex and dry eye syndrome caused by meibomain gland dysfunction and used for preventing and treating infection of acanthamoeba polyphaga and anaerobic bacteria in a corneal contact lens wearing process. The ornidazole ophthalmic gel consists of the ornidazole and a pharmaceutically acceptable carrier, and every 100 grams of ornidazole ophthalmic gel contains 0.1 to 3.0 grams of ornidazole.
Description
Technical field
The present invention relates to a kind of effective ingredient ornidazole, process the gel for eye use dosage form first, be applied to the application of eye anthelmintic demodicid mite, thorn ameba protozoon and anaerobic infection control.
Background technology
Intractable blepharitis, hordeolum, conjunctivitis and meibomian gland dysfunction (that research recently confirms is relevant with the anthelmintic mite infestationss for meibomain gland dysfunction, the xerophthalmia due to MGD) (international ophthalmology is scanned, and 2007,3:149; Clinical ophthalmology magazine, 2010,4:358).Mu Jian to 91 routine blepharitis patient anthelmintic demodicid mite recall rates 90% (clinical ophthalmology magazine, 2010,4:358).Gao to margo palpebrae portion anthelmintic demodicid mite recall rate 100% (Invest ophthalmol vis sci, 2005,46:3089).Acanthamoeba property keratitis is the serious blinding property oculopathy that infects owing to thorn ameba protozoon, and 75% has wearing of contact lens historical, can cause corneal ulcer even perforation of cornea.Ornidazole is to kill the anthelmintic demodicid mite and up-to-date, the most effective unique medicine of thorn ameba protozoon, and the infection of car one-tenth industry application of self-made metronidazole eye drop prevention corneal contact lens thorn ameba protozoon (the Shandong medical journal, 2008,3:246).The conjunctival sac time of staying of common metronidazole eye drop is short, curative effect is low.The eye medicinal preparation of present domestic listing, also not seeing has the ophthalmic preparation of killing anthelmintic demodicid mite and thorn ameba protozoon, does not still have the report of the research and the pharmaceutical production of ornidazole gel for eye use.
Summary of the invention
There is not the technological deficiency that the eye medicinal preparation of killing anthelmintic demodicid mite and thorn ameba protozoon is arranged in the prior art in order to overcome.The purpose of this invention is to provide a kind of eye medicinal preparation of killing anthelmintic demodicid mite and thorn ameba protozoon infection; Specifically provide a kind of ornidazole gel for eye use; More particularly; Provide the gel for eye use of xerophthalmia due to blepharitis, hordeolum, conjunctivitis and the meibomian gland dysfunction of a kind of prophylactic treatment anthelmintic mite infestationss, the gel for eye use that thorn ameba protozoon infects in a kind of prophylactic treatment wearing of contact lens process is provided.Another object of the present invention is the method for preparing and the application of ornidazole gel for eye use in preparation prophylactic treatment eye part disease medicine of ornidazole gel for eye use.
In order to realize above-mentioned goal of the invention, technical scheme of the present invention is:
The ornidazole gel for eye use is the single preparations of ephedrine of ornidazole, according to preparation title and the corresponding to principle of raw material, and these article called after ornidazole gel for eye use, English is called: Ornidazole Ophthalmic Gel.Gel for eye use is the opthalmological dosage form of State Food and Drug Administration's approval, and this gel for eye use dosage form (Ophthalmic Gel) also is called gel-type eye ointment, gel-type eye drop, gel type eye drop.
This ornidazole gel for eye use; It contains the medicine activity component ornidazole and the medicine acceptable carrier is formed; The ornidazole consumption is 0.1~5.0g in every by weight 100g ornidazole gel for eye use; The ornidazole preferable amount is 0.5~3.0g in every by weight 100g ornidazole gel for eye use, in every by weight 100g ornidazole gel for eye use ornidazole more preferably consumption be 1.0g.This ornidazole gel for eye use contains ornidazole 0.1~5.0g, card pool nurse 0.1~10.0g, hydroxypropyl methylcellulose 0.04~20.0g, the rigid Oleum Ricini 0.01~5.0g of hydrogenation, boric acid 0.3~3.0g, propylene glycol 0.1~5.0g, sodium chloride 0.5~1.0g, ethyl hydroxybenzoate 0.01~0.05g in every by weight 100g ornidazole gel for eye use.This ornidazole gel for eye use, preferable amount: contain ornidazole 1.0g, card pool nurse 0.8g, hydroxypropyl methylcellulose 0.2g, the rigid Oleum Ricini 1.0g of hydrogenation, boric acid 1.0g, propylene glycol 1.0g, sodium chloride 0.5g, ethyl hydroxybenzoate 0.025g in every 100g ornidazole gel for eye use.
This ornidazole gel for eye use Chinese medicine acceptable carrier also refers to the medicine acceptable auxiliary.The medicine acceptable carrier is one or more in gel-type vehicle, isoosmotic adjusting agent, PH regulator, water for injection, the antiseptic.In preparation tinidazole gel for eye use process, preferably select the stable good and less medicine acceptable carrier of zest.Gel-type vehicle is one or more in card pool nurse, the rigid Oleum Ricini of hydrogenation, dextran, glycerol, poloxamer, tween, hyaluronic acid sodium, methylcellulose, hydroxy methocel, hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose, polyvinyl alcohol, Polyethylene Glycol, the polyvinylpyrrolidone; The gel-type vehicle consumption is 0.1~40.0% in the gel for eye use, preference card pool nurse, the rigid Oleum Ricini of hydrogenation, hyaluronic acid sodium, hydroxypropyl methylcellulose.Isoosmotic adjusting agent is one or more in glycerol, propylene glycol, glycerin, sodium chloride, glucose, mannitol, the sorbitol, and the isoosmotic adjusting agent consumption is 0~8.0% in the gel for eye use, preferred propylene glycol, sodium chloride.The PH regulator is one or more in boric acid, Borax, glacial acetic acid, hydrochloric acid, sodium hydroxide, triethanolamine, citric acid, sodium citrate, tartaric acid, sodium tartrate, sodium hydrogen phosphate, sodium dihydrogen phosphate, the phosphoric acid; Gel for eye use PH is adjusted between 4.0 to 9.0 preferred boric acid, Borax, sodium hydroxide with the PH regulator.Antiseptic is one or more in chlorocresol, nipalgin, methyl hydroxybenzoate, propylparaben, chlorobutanol, phenoxyethanol, chlorhexidine, oradol, benzalkonium chloride, benzalkonium bromide, the ethyl hydroxybenzoate; The antiseptic consumption is 0~0.2% in the gel for eye use, preferred nipalgin, chlorobutanol, ethyl hydroxybenzoate.
The method for preparing of ornidazole gel for eye use of the present invention: ornidazole is dissolved with an amount of water for injection; Stir with hydroxypropyl methylcellulose, the rigid Oleum Ricini of hydrogenation, propylene glycol, sodium chloride, boric acid, ethyl hydroxybenzoate respectively; Heating is dissolved it fully, forms ornidazole solution; To block the pool nurse and be spread in the water for injection, be swelled into gel solution, add above-mentioned ornidazole solution, pressure sterilizing, cooling, filtration, packing, packing promptly get.
Ornidazole gel for eye use of the present invention still is a kind of invention of clinical ophthalmology purposes, also is the application of ornidazole gel for eye use in preparation control eye part disease medicine, and the ornidazole consumption is 0.1~5.0g in every by weight 100g ornidazole gel for eye use.
The pharmacological action of ornidazole gel for eye use of the present invention and clinical treatment mechanism are following:
Vermiform mite (Demodex) is a kind of small-sized permanent parasitic mite, and what parasitize human body has hair follicle anthelmintic demodicid mite and a sebum anthelmintic demodicid mite, and in a single day human body infects the anthelmintic demodicid mite, without killing anthelmintic demodicid mite Drug therapy, will not heal all the life.Eyelid is rich in fine and close eyelashes capsule and enriches sebaceous gland and tarsal glands; It is the easy infection position of anthelmintic demodicid mite; In case anthelmintic mite infestationss eyelashes capsule, eyelashes sebaceous gland and tarsal glands will cause that xerophthalmia takes place due to blepharitis, hordeolum, conjunctivitis and the tarsal glands functional disorder.At present on the opthalmological market, do not have the ophthalmic preparation of killing the anthelmintic demodicid mite arranged, cause anthelmintic mite infestationss property eye inflammation prolongedly do not heal, obstinate stored for a long time.
Acanthamoeba property keratitis is a kind of serious blinding property oculopathy, is by due to thorn ameba protozoon (Acanthamoeba) infection of type free life.Bibliographical information is arranged, and 52~88.9% Acanthamoeba property keratitis betide in the wearing of contact lens process, because due to contact lens, conditioning liquid, tap water and mirror case etc. are polluted by thorn ameba protozoon.Owing on the opthalmological market, do not have and kill the thorn ameba protozoon ophthalmic preparation, cause the sickness rate of Acanthamoeba property keratitis to increase year by year, part patient even cause blindly.
Ornidazole is the third generation nitro glyoxaline synthetic antibacterial drug after metronidazole, tinidazole, another name: Tiberal, dripping must dew, ornidazole, first nitre miaow chloropropyl alcohol, difficult to understand sharp appropriate, English name Ornidazole.Ornidazole has the unique effect of killing anthelmintic demodicid mite, thorn ameba protozoon and wide spectrum anaerobe resistant, is the choice drug of the above-mentioned eye infected by microbes of prophylactic treatment.
The present invention selects to have the strong ornidazole of effectively killing anthelmintic demodicid mite and thorn ameba protozoon infection as medicine activity component; Select the medicine acceptable carrier; Be prepared into eye-gel preparation through modern eye-gel preparation technology, be used for application at preparation prophylactic treatment eye part disease medicine.
Good effect of the present invention: the present invention has filled up the blank of domestic ophthalmic remedy, and specifically: having filled up not have in the ornidazole medicine to have does not have the blank that the ornidazole medicine is arranged in gel for eye use dosage form and the gel for eye use dosage form.More positive effect is, filled up the ophthalmic preparation of the xerophthalmia due to blepharitis, hordeolum, conjunctivitis and the meibomian gland dysfunction of prophylactic treatment eye anthelmintic mite infestationss; Fill up the ophthalmic preparation of the Acanthamoeba property keratitis due to the prophylactic treatment thorn ameba protozoon infects, particularly provide wearing of contact lens person to prevent the application in the thorn ameba protozoon infection medicine.The ornidazole gel for eye use has unrivaled advantage with respect to ordinary eye drops and common eye ointment dosage form, and gel for eye use time of staying in conjunctival sac is long, is easy to drug absorption, and clear gel does not cause blurred vision, all can use round the clock.Xerophthalmia due to blepharitis, hordeolum, conjunctivitis and the meibomian gland dysfunction is the most common oculopathy of ophthalmology, and wearing of contact lens person has 400,000,000 crowds approximately, and the ornidazole gel for eye use of this invention has very big society and economy benefit.The present invention produces outstanding substantial variation, has outstanding substantive distinguishing features and obvious improvement.
Ornidazole gel for eye use of the present invention through lagophthalmos repeatedly the local irritation experimentation of coating show these article nonirritant; Medicine is stablized experimentation and shown, and is more stable under these article room temperature.The ornidazole gel for eye use, through the clinical efficacy test evaluation, the effective xerophthalmia due to prophylactic treatment blepharitis, hordeolum, conjunctivitis and the meibomian gland dysfunction.
The specific embodiment
Through following embodiment, can understand the excellent effect that inventive concept of the present invention and invention obtain better.The embodiment that is provided just in order to help to understand the present invention, rather than constitutes the invention protection domain is played restriction, under design prerequisite of the present invention, the present invention is simply changed, and all belongs to the scope of requirement protection of the present invention.
Embodiment 1:
Prescription is formed: ornidazole 1.0g, card pool nurse 0.8g, hydroxypropyl methylcellulose 0.2g, the rigid Oleum Ricini 1.0g of hydrogenation, boric acid 1.0g, propylene glycol 1.0g, sodium chloride 0.5g, ethyl hydroxybenzoate 0.025g; Water for injection adds to full dose, processes 100g ornidazole gel for eye use.
Method for preparing: ornidazole is dissolved with an amount of water for injection, stir with hydroxypropyl methylcellulose, the rigid Oleum Ricini of hydrogenation, boric acid, propylene glycol, sodium chloride, ethyl hydroxybenzoate respectively, heating is dissolved it fully, forms ornidazole solution; To block the pool nurse and be spread in the water for injection, be swelled into gel solution, add above-mentioned ornidazole solution, pressure sterilizing, cooling, filtration, packing, packing promptly get.
Embodiment 2:
Prescription is formed: ornidazole 0.75g, card pool nurse 0.8g, hydroxypropyl methylcellulose 0.2g, the rigid Oleum Ricini 1.0g of hydrogenation, boric acid 1.0g, propylene glycol 1.0g, sodium chloride 0.5g, ethyl hydroxybenzoate 0.025g; Water for injection adds to full dose, processes 100g ornidazole gel for eye use.
Method for preparing: with embodiment 1.
Embodiment 3:
Prescription is formed: ornidazole 5.0g, card pool nurse 0.8g, hydroxypropyl methylcellulose 0.2g, the rigid Oleum Ricini 1.0g of hydrogenation, boric acid 1.0g, propylene glycol 1.0g, sodium chloride 0.5g, ethyl hydroxybenzoate 0.025g; Water for injection adds to full dose, processes 100g ornidazole gel for eye use.
Method for preparing: with embodiment 1.
Embodiment 4:
Prescription is formed: ornidazole 0.1~5.0g, card pool nurse 0.1~10.0g, hydroxypropyl methylcellulose 0.04~20.0g, the rigid Oleum Ricini 0.01~5.0g of hydrogenation, boric acid 0.3~3.0g, propylene glycol 0.1~5.0g, sodium chloride 0.5~1.0g, ethyl hydroxybenzoate 0.01~0.05g; Water for injection adds to full dose, processes 100g ornidazole gel for eye use.
Method for preparing: with embodiment 1.
Embodiment 5: ornidazole gel for eye use lagophthalmos irritant test
Get 4 of test rabbits, right eye is as the test eye, and left eye is as the contrast eye, and right eye drips 1.0% ornidazole gel for eye use, splashes into 1 at every turn, and every day, eye drip was 4 times, and eye drip is 7 days continuously.Through naked eyes and slit lamp examination, observe conjunctiva, cornea and iris IR situation.Drip the experimental eye of ornidazole gel for eye use, with left eye contrast eye, eyes all do not have any IR.
Embodiment 6: the clinical trial therapeutic evaluation
Case is selected: select the wearing of contact lens patient, amount to 20 eyes, use 1.0% ornidazole gel for eye use of preparation, be coated with for 4 times every day and suffer from eye, continuous use 14 days is observed eye conjunctiva and cornea situation.Any discomfort symptom and conjunctiva anomaly of cornea sign do not take place in the Total Test case.
Embodiment 7: the clinical trial therapeutic evaluation
Case is selected: the diagnostic criteria of anthelmintic mite infestationss property oculopathy, and one is the clinical xerophthalmia due to blepharitis, hordeolum, conjunctivitis and the tarsal glands functional disorder that meets, inspection finds that margo palpebrae is congested, the conjunctival congestion sign; Another is that anthelmintic demodicid mite microscopy is positive: clinical diagnosis patient's eyelid eyelashes are pulled out 4, eyelashes are placed on the microscope slide, on microscope slide, drip normal saline, cover microscope slide, microscopically counting anthelmintic demodicid mite, it is positive to detect anthelmintic demodicid mite person.Meet clinical diagnosis and eyelashes anthelmintic demodicid mite microscopy positive person, amount to 18 eyes.Use 1.0% ornidazole gel for eye use of preparation, be coated with for 4 times every day and suffer from eye, treat 21 days continuously after, observe eye symptom, sign and eyelashes anthelmintic demodicid mite microscopy result.Suffer from an eye symptom, sign disappears and eyelashes anthelmintic demodicid mite microscopy negative patient, is judged as treatment effectively.Ornidazole gel for eye use of the present invention, through the clinical experiment therapeutic evaluation, total effective rate is 90%.
Claims (10)
1. ornidazole gel for eye use is characterized in that: it contains the medicine activity component ornidazole and the medicine acceptable carrier is formed, and the ornidazole consumption is 0.1~5.0g in every by weight 100g ornidazole gel for eye use.
2. ornidazole gel for eye use according to claim 1 is characterized in that: the ornidazole consumption is 0.5~3.0g in every by weight 100g ornidazole gel for eye use.
3. ornidazole gel for eye use according to claim 1 is characterized in that: the ornidazole consumption is 1.0g in every by weight 100g ornidazole gel for eye use.
4. ornidazole gel for eye use according to claim 1 is characterized in that: contain ornidazole 0.1~5.0g, card pool nurse 0.1~10.0g, hydroxypropyl methylcellulose 0.04~20.0g, the rigid Oleum Ricini 0.01~5.0g of hydrogenation, boric acid 0.3~3.0g, propylene glycol 0.1~5.0g, sodium chloride 0.5~1.0g, ethyl hydroxybenzoate 0.01~0.05g in every by weight 100g ornidazole gel for eye use.
5. ornidazole gel for eye use according to claim 1 is characterized in that: contain ornidazole 1.0g, card pool nurse 0.8g, hydroxypropyl methylcellulose 0.2g, the rigid Oleum Ricini 1.0g of hydrogenation, boric acid 1.0g, propylene glycol 1.0g, sodium chloride 0.5g, ethyl hydroxybenzoate 0.025g in every 100g ornidazole gel for eye use.
6. ornidazole gel for eye use according to claim 1 is characterized in that: the medicine acceptable carrier is one or more in gel-type vehicle, isoosmotic adjusting agent, PH regulator, water for injection, the antiseptic.
7. ornidazole gel for eye use according to claim 6; It is characterized in that: gel-type vehicle is one or more in card pool nurse, the rigid Oleum Ricini of hydrogenation, dextran, glycerol, poloxamer, tween, hyaluronic acid sodium, methylcellulose, hydroxy methocel, hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose, polyvinyl alcohol, Polyethylene Glycol, the polyvinylpyrrolidone, and the gel-type vehicle consumption is 0.1~40.0% in the gel for eye use; Isoosmotic adjusting agent is one or more in glycerol, propylene glycol, glycerin, sodium chloride, glucose, mannitol, the sorbitol, and the isoosmotic adjusting agent consumption is 0~8.0% in the gel for eye use; The PH regulator is one or more in boric acid, Borax, glacial acetic acid, hydrochloric acid, sodium hydroxide, triethanolamine, citric acid, sodium citrate, tartaric acid, sodium tartrate, sodium hydrogen phosphate, sodium dihydrogen phosphate, the phosphoric acid, with the PH regulator gel for eye use PH is adjusted between 4.0 to 9.0; Antiseptic is one or more in chlorocresol, nipalgin, methyl hydroxybenzoate, propylparaben, chlorobutanol, phenoxyethanol, chlorhexidine, oradol, benzalkonium chloride, benzalkonium bromide, the ethyl hydroxybenzoate, and the antiseptic consumption is 0~0.2% in the gel for eye use.
8. according to the method for preparing of claim 4 or 5 described ornidazole gel for eye use; It is characterized in that: ornidazole is dissolved with an amount of water for injection; Stir with hydroxypropyl methylcellulose, the rigid Oleum Ricini of hydrogenation, propylene glycol, sodium chloride, boric acid, ethyl hydroxybenzoate respectively; Heating is dissolved it fully, forms ornidazole solution; To block the pool nurse and be spread in the water for injection, be swelled into gel solution, add above-mentioned ornidazole solution, pressure sterilizing, cooling, filtration, packing, packing promptly get.
9. ornidazole gel for eye use according to claim 1 is characterized in that: gel for eye use is meant gel-type eye ointment, gel-type eye drop, gel type eye drop.
10. the purposes of ornidazole gel for eye use is characterized in that: the application of ornidazole gel for eye use in preparation control eye part disease medicine, the ornidazole consumption is 0.1~5.0g in every by weight 100g ornidazole gel for eye use.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100711413A CN102525889A (en) | 2012-03-19 | 2012-03-19 | Ornidazole ophthalmic gel and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100711413A CN102525889A (en) | 2012-03-19 | 2012-03-19 | Ornidazole ophthalmic gel and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102525889A true CN102525889A (en) | 2012-07-04 |
Family
ID=46334723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012100711413A Pending CN102525889A (en) | 2012-03-19 | 2012-03-19 | Ornidazole ophthalmic gel and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102525889A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102961324A (en) * | 2012-11-16 | 2013-03-13 | 沈阳药科大学 | Gel for lysozyme eye and preparation method thereof |
CN106551929A (en) * | 2016-11-05 | 2017-04-05 | 罗洋 | New application of the Ornidazole in treatment acne rosacea medicine |
CN109562166A (en) * | 2017-04-28 | 2019-04-02 | 苏州思坦维生物技术股份有限公司 | A kind of medical composite for eye and application thereof |
CN109700805A (en) * | 2018-12-29 | 2019-05-03 | 罗洋 | Ornidazole is as controlling application of the demodicidosis drug in clinic |
-
2012
- 2012-03-19 CN CN2012100711413A patent/CN102525889A/en active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102961324A (en) * | 2012-11-16 | 2013-03-13 | 沈阳药科大学 | Gel for lysozyme eye and preparation method thereof |
CN102961324B (en) * | 2012-11-16 | 2014-06-25 | 沈阳药科大学 | Gel for lysozyme eye and preparation method thereof |
CN106551929A (en) * | 2016-11-05 | 2017-04-05 | 罗洋 | New application of the Ornidazole in treatment acne rosacea medicine |
CN109562166A (en) * | 2017-04-28 | 2019-04-02 | 苏州思坦维生物技术股份有限公司 | A kind of medical composite for eye and application thereof |
CN109700805A (en) * | 2018-12-29 | 2019-05-03 | 罗洋 | Ornidazole is as controlling application of the demodicidosis drug in clinic |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102552114A (en) | Metronidazole ophthalmic gel and preparation method and application thereof | |
EP3515420B1 (en) | Pharmaceutical compositions for use in the therapy of blepharitis | |
ES2709180T3 (en) | Brimonidine and timolol solutions without preservatives | |
ES2604816B1 (en) | Pharmaceutical composition of tramadol for ophthalmic use | |
EP2316420B1 (en) | Topical ophthalmic composition to reduce pain | |
CN112516080B (en) | Ophthalmic pharmaceutical composition, and preparation method and application thereof | |
US10973758B2 (en) | Methods of eye treatment using therapeutic compositions containing dipyridamole | |
CN103040888A (en) | Ophthalmologic external preparation, as well as preparation method and application thereof | |
KR20210127197A (en) | Formulation of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile | |
CN111544390B (en) | Traditional Chinese medicine preparation for treating meibomian gland dysfunction and/or allergic conjunctivitis, ultrasonic atomization and nano-spray preparation and preparation method | |
CN102525889A (en) | Ornidazole ophthalmic gel and preparation method and application thereof | |
JP2022541854A (en) | Compositions and methods for treating presbyopia | |
KR102116303B1 (en) | Formulations and related methods for treating ocular surface diseases | |
CN103432069A (en) | Ofloxacin eye drop without bacteriostatic agent and preparation method of ofloxacin eye drop | |
US20180221407A1 (en) | Ophthalmic compositions for therapeutic and prophylactic uses | |
CN109846820B (en) | Ofloxacin eye drops and preparation method thereof | |
Thakur et al. | Promising implication of ocuserts in ocular disease | |
KR20190071674A (en) | Ophthalmic preparations and ophthalmic preparations | |
CN102641267A (en) | Externally-applied skin gel as well as preparation method and application thereof | |
CN102579321A (en) | Tinidazole ophthalmic gel, and preparation method and application thereof | |
CN109453151B (en) | Pharmaceutical composition for eyes, preparation method and application thereof | |
KR20230098630A (en) | Low dose synergistic ophthalmic compositions effective for the prevention, control and eradication of presbyopia | |
Wagh et al. | Drug delivery and pharmacotherapy for dry eye disease | |
CN105213418A (en) | Preoperative compound eye drops of a kind of ophthalmology and preparation method thereof | |
CN105902686A (en) | In-situ gel eyewash containing nano-carbon crystals and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120704 |